Ochola Lyticia A, Ng'wena Gideon M, Noland Gregory S, Ondigo Bartholomew N, Ayodo George, John Chandy C
Department of Biomedical Sciences and Technology, School of Public Health and Community Development, Maseno University, Maseno ; Kenya Medical Research Institute, University of Minnesota Malaria Program, Kisumu, Kenya.
Department of Medical Physiology, School of Medicine, Maseno University, Maseno, Kenya.
J Glob Infect Dis. 2013 Oct;5(4):131-7. doi: 10.4103/0974-777X.122001.
MB2 is a novel Plasmodium falciparum antigen of unknown function expressed in pre-erythrocytic and blood stages of infection in the human host. Interferon-gamma (IFN-γ) and interleukin (IL)-10 responses to other P. falciparum antigens have been associated with protection from clinical malaria, but these responses have not been studied for MB2. The present study was undertaken to characterize IFN-γ and IL-10 responses to P. falciparum MB2 antigen in adults living in areas of differing malaria transmission in Western Kenya.
Cytokine responses to two 9-mer MB2 peptides predicted to be human leukocyte antigen (HLA) class I restricted T-cell epitopes were measured by enzyme-linked immunosorbent assay (ELISA) (IFN-γ and IL-10) and enzyme-linked immunosorbent spot (ELISPOT) (IFN-γ) in adults (n = 228) in areas of unstable and stable malaria transmission. HLA class I restriction of responses was assessed in a sub-group of the study population.
IFN-γ and IL-10 responses to MB2 peptides by ELISA were observed in both sites with no significant difference in prevalence (IFN-γ, unstable transmission area, 18.8%, stable transmission area, 27.5%, P = 0.33; IL-10, unstable transmission area, 22.5%, stable transmission area, 25.0%, P = 0.78). Prevalence of IFN-γ responses by ELISPOT was also similar in both areas (unstable, 10.8%, stable, 10.9%, P = 0.98). Neither IFN-γ nor IL-10 responses showed evidence of HLA class I restriction.
MB2 induces IFN-γ and IL-10 responses in adults living in both stable and unstable malaria transmission areas. Future studies should assess if these responses are associated with protection from clinical malaria.
MB2是一种新型的恶性疟原虫抗原,其功能未知,在人类宿主感染的红细胞前期和血液阶段表达。对其他恶性疟原虫抗原的γ干扰素(IFN-γ)和白细胞介素(IL)-10反应与预防临床疟疾有关,但尚未对MB2的这些反应进行研究。本研究旨在描述肯尼亚西部不同疟疾传播地区成年人对恶性疟原虫MB2抗原的IFN-γ和IL-10反应特征。
通过酶联免疫吸附测定(ELISA)(检测IFN-γ和IL-10)和酶联免疫斑点法(ELISPOT)(检测IFN-γ)测量了对两种预测为人白细胞抗原(HLA)I类限制性T细胞表位的9肽MB2的细胞因子反应,研究对象为不稳定和稳定疟疾传播地区的成年人(n = 228)。在研究人群的一个亚组中评估了反应的HLA I类限制性。
两个地点均观察到通过ELISA对MB2肽的IFN-γ和IL-10反应,患病率无显著差异(IFN-γ,不稳定传播地区为18.8%,稳定传播地区为27.5%,P = 0.33;IL-10,不稳定传播地区为22.5%,稳定传播地区为25.0%,P = 0.78)。两个地区通过ELISPOT检测的IFN-γ反应患病率也相似(不稳定地区为10.8%,稳定地区为10.9%,P = 0.98)。IFN-γ和IL-10反应均未显示HLA I类限制性的证据。
MB2在稳定和不稳定疟疾传播地区的成年人中均可诱导IFN-γ和IL-10反应。未来的研究应评估这些反应是否与预防临床疟疾有关。